They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

As more cancers are being linked to the human papillomavirus (HPV), including cancers showing up in younger-than-average patients, a local doctor is promoting the use of the HPV vaccine, which is ...

Those were partially offset by lower sales of diabetic medicines Januvia and Janumet, and lower combined sales of the human papillomavirus, or HPV, vaccine Gardasil/Gardasil 9, due to reduced ...

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

HPV vaccines aim to prevent the development of HPV-related cancers by stopping the viral infection from taking hold in the ...

The increase is driven by growth in oncology and cardiovascular, partially offset by declines in diabetes, vaccines ... to temporarily pause Gardasil/Gardasil 9 shipments into China beginning ...

Excluding the impact of foreign exchange, sales increased 9%. Merck reported adjusted ... Merck reported a decline of 17% in sales of Gardasil to $1.55 billion, a vaccine that prevents cancer ...